These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28692842)

  • 1. PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A.
    Pasca S; Milan M; Sarolo L; Zanon E
    Thromb Res; 2017 Sep; 157():58-63. PubMed ID: 28692842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden.
    Henry N; Jovanović J; Schlueter M; Kritikou P; Wilson K; Myrén KJ
    J Med Econ; 2018 Apr; 21(4):318-325. PubMed ID: 29139314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real pandemic world results of pharmacokinetic-tailored personalized prophylaxis of bleeds in Polish children and adolescents with severe hemophilia A.
    Urasiński T; Paczóska K; Badowska W; Bobrowska H; Dakowicz Ł; Dobaczewski G; Latos-Grażyńska E; Karolczyk G; Klukowska A; Kołtan A; Wojdalska M; Łaguna P; Niedźwiedzki M; Pietrys D; Radoń-Proskura J; Radwańska M; Rurańska I; Szczepański T; Wasiński D; Woźnica-Karczmarz I; Zielezińska K; Królak A; Ociepa T
    Front Pediatr; 2023; 11():1084539. PubMed ID: 36911027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Savings without changing: How to use the MyPKfit® device to improve treatment strategies in a cohort of patients with haemophilia A.
    Pasca S; Zanon E
    Thromb Res; 2019 Nov; 183():1-3. PubMed ID: 31505377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in clinical outcomes and replacement factor VIII use in patients with haemophilia A after factor VIII pharmacokinetic-guided prophylaxis based on Bayesian models with myPKFiT
    Mingot-Castellano ME; Parra R; Núñez R; Martorell M
    Haemophilia; 2018 Sep; 24(5):e338-e343. PubMed ID: 30028549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Pharmacokinetic-Guided Prophylaxis Versus Standard Prophylaxis in Adults with Severe Hemophilia A in China.
    Gu C; Huang H; Han Y
    Adv Ther; 2022 Aug; 39(8):3777-3788. PubMed ID: 35768709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Climbing therapy under PK-tailored prophylaxis.
    Stemberger M; Schmit E; Czepa D; Kurnik K; Spannagl M
    Hamostaseologie; 2014; 34 Suppl 1():S13-6. PubMed ID: 25382764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian pharmacokinetic-guided prophylaxis with recombinant factor VIII in severe or moderate haemophilia A.
    Megías-Vericat JE; Bonanad S; Haya S; Cid AR; Marqués MR; Monte E; Pérez-Alenda S; Bosch P; Querol F; Poveda JL
    Thromb Res; 2019 Feb; 174():151-162. PubMed ID: 30634166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The principles of PK-tailored prophylaxis.
    Reininger AJ; Chehadeh HE
    Hamostaseologie; 2013; 33 Suppl 1():S32-5. PubMed ID: 24169861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing.
    Nagao A; Yeung CHT; Germini F; Suzuki T
    Thromb Res; 2019 Jan; 173():79-84. PubMed ID: 30496937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Jul; 33(7):1223-1230. PubMed ID: 28326849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-guided prophylaxis improved clinical outcomes in paediatric patients with severe haemophilia A.
    Huang K; Zhen Y; Li G; Wu X; Chen Z; Wu R
    Haemophilia; 2021 Jul; 27(4):e450-e457. PubMed ID: 34015176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling.
    Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV
    Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended half-life pegylated, full-length recombinant factor VIII for prophylaxis in children with severe haemophilia A.
    Mullins ES; Stasyshyn O; Alvarez-Román MT; Osman D; Liesner R; Engl W; Sharkhawy M; Abbuehl BE
    Haemophilia; 2017 Mar; 23(2):238-246. PubMed ID: 27891721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic use of factor VIII: an economic evaluation.
    Bohn RL; Avorn J; Glynn RJ; Choodnovskiy I; Haschemeyer R; Aledort LM
    Thromb Haemost; 1998 May; 79(5):932-7. PubMed ID: 9609224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored prophylaxis in children with severe hemophilia: A four-year Iranian study.
    Baghaipour M; Salimi T; Bahoush G; Jazebi M; Ala F; Azizi Saraji A; Dorgalaleh A; Moazezi Nekoei Asl SS; Mohamadamini M; Tabibian S
    Transfus Apher Sci; 2021 Dec; 60(6):103212. PubMed ID: 34257016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels.
    Ljung R; Fischer K; Carcao M; Santagostino E; Manco-Johnson MJ; Mathew P;
    Thromb Haemost; 2016 May; 115(5):913-20. PubMed ID: 26791493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C; Watts RG
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized Prophylaxis with myPKFiT
    Antonazzo IC; Cortesi PA; Zanon E; Pasca S; Morfini M; Santoro C; De Cristofaro R; Di Minno G; Cozzolino P; Mantovani LG
    Medicina (Kaunas); 2023 Dec; 60(1):. PubMed ID: 38256294
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.